Bevacizumab biosimilar - Allergan/Amgen

Drug Profile

Bevacizumab biosimilar - Allergan/Amgen

Alternative Names: ABP-215; Bevacizumab-awwb; Mvasi

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; Watson Pharmaceuticals
  • Developer Allergan; Amgen
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 14 Sep 2017 Registered for Cervical cancer (Recurrent, Metastatic disease, Combination therapy) in USA (IV)
  • 14 Sep 2017 Registered for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in USA (IV)
  • 14 Sep 2017 Registered for Colorectal cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top